α受体阻滞剂在高血压治疗中仍有用武之地  

α-Receptor blockers are still useful in the treatment of hypertension

作　　者：徐少坤 谢建洪[1] XU Shaokun;XIE Jianhong(Department of Gerontology(Hypertension),Zhejiang Provincial People's Hospital,Hangzhou 310014,Zhejiang Province,China)

机构地区：[1]浙江省人民医院老年医学科(高血压科),浙江杭州310014

出　　处：《世界临床药物》2023年第8期773-777,共5页World Clinical Drug

摘　　要：α受体阻滞剂是治疗高血压的经典药物,然而目前主要的高血压指南均不再推荐其作为一线降压药物。近年来,随着相关临床研究结果的不断更新,α受体阻滞剂的临床应用价值再次受到关注,但临床应用缺乏充分、合理的指导,阻碍该类药物充分发挥其治疗作用。该文通过对近期发表的《α受体阻滞剂降压治疗中国专家共识》进行解读,以期能为α受体阻滞剂的合理应用提供指导。α-Receptor blockers are the classic drugs for hypertension,but they are no longer recommended as first-line antihypertensive agents in major hypertension guidelines.In recent years,with the continuous updating of relevant clinical trial results,the clinical application value ofα-blockers has once again attracted attention,but its clinical application lacks sufficient and reasonable guidance,which hinders the important therapeutic effects ofα-blockers.This article interpreted the recently published Chinese Expert Consensus onα-Blockers for Antihypertensive Therapy,in order to provide guidance for the rational application ofα-receptor blockers.

关 键 词：高血压 Α受体阻滞剂 共识解读 

分 类 号：R972.4[医药卫生—药品] R544.1[医药卫生—药学]